Objective  To investigate the prevalence of metabolic associated fatty liver disease (MAFLD) and its influencing factors in an administrative district of Wuhan. 

Methods  The study in-cluded 20,502 residents aged 65 years or older receiving a free physical examination in this area in 2018. The prevalence of MAFLD among different genders, ages and BMI grades were compared. Uni-variate analysis was performed using the χ2 test and the OR with associated 95% CI for MAFLD was cal-culated using the multivariate non-conditional logistic regression method. 

Results The prevalence of MAFLD was 38.75%, being higher in women than men (41.44% vs. 35.53%), and those aged 65~69 years had the highest prevalence (40.91%). The prevalence of MAFLD also showed an increasing trend with increasing BMI (P<0.001). The Logistic regression results showed that, after adjusting for age, gender and education levels, drinking alcohol [OR=1.348, 95%CI(1.181, 1.539)], dyslipidemia [OR=1.769, 95%CI(1.655, 1.891)], hypertension [OR=1.354, 95%CI(1.259, 1.456)], overweight/obesity [OR=4.859, 95%CI(4.476, 5.274)], central obesity [OR=2.517, 95%CI(2.348, 2.698)], ALT abnormity [OR=2.223, 95%CI(1.906, 2.592)] and impaired fasting glucose [OR=1.485, 95%CI(1.346, 1.638)] may be risk factors for the increased prevalence of MAFLD. 

Conclusion The prevalence of MAFLD among residents aged 65 years and older is high in this district. We should enhance health education and con-trol alcohol consumption. Besides, targeted interventions should be implemented for residents with dyslipidemia and hypertension, and for those elderly residents with overweight/obesity and central obesity. Routine monitoring of people with abnormal ALT and impaired fasting blood glucose also needs to be increased.

1.Li J, Zou B, Yeo YH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2019, 4(5): 389-398. DOI: 10.1016/S2468-1253(19)30039-1.

2.Wang X, Wu S, Yuan X, et al. Metabolic dysfunction-associated fatty liver disease and mor-tality among Chinese adults: a prospective cohort study[J]. J Clin Endocrinol Metab, 2021, dgab644. DOI: 10.1210/clinem/dgab644.

3.Fan J, Luo S, Ye Y, et al. Prevalence and risk factors of metabolic associated fatty liver dis-ease in the contemporary South China population[J]. Nutr Metab (Lond), 2021, 18(1): 82. DOI: 10.1186/s12986-021-00611-x.

4.Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunc-tion-associated fatty liver disease: an  international expert consensus statement[J]. J Hepa-tol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.

5.Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312.

6.American Diabetes Association. Diagnosis and classification of diabetes mellitus[J]. Diabe-tes Care, 2011, 34(Suppl 1): S62-S69. DOI: 10.2337/dc11-S062.

7.World Health Organization. Regional Office for the Western Pacific. (2000). The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Austral-ia[EB/OL]. (2000-02) [2021-10-11]. https://apps.who.int/iris/handle/10665/206936.

8.中华人民共和国国家卫生和计划生育委员会. 成人体重判定: WS/T 428-2013[S]. 2013. [National Health and Family Planning Commission of the People's Republic of China. Adult weight de-termination: WS/T 428-2013[S]. 2013.] 

9.余双彬，俞梦璐，陈曦，等. 四川省绵阳市成人脂肪肝流行现况及其代谢异常情况分析[J]. 中国医学科学院学报, 2019, 41(3): 323-330. [Yu SB, Yu ML, Chen X, et al. Prevalence and metabolic abnor-malities of fatty liver disease among adults in Mianyang city, Sichuan province[J]. Acta Aca-demiae Medicinae Sinicae, 2019, 41(3): 323-330.] DOI: 10.3881/j.issn.1000-503X.10720.

10.中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. [Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 di-abetes mellitus in China (2020 edition) [J]. Chinese Journal of Diabetes Mellitus, 2021, 13(4): 315-409.] DOI: 10.3760/cma.j.cn115791-20210221-00095. 

11.中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南（2016年修订版）[J]. 中华全科医师杂志, 2017, 16(1): 15-35. [Joint Committee Issued Chinese Guideline for the Manage-ment of Dyslipidemia. 2016 Chinese guideline for the management of dyslipidemia in adults[J]. Chinese Journal of General Practitioners, 2017, 16(1): 15-35.] DOI: 10.3760/cma.j.issn.1671-7368.2017.01.006.

12.Li H, Guo M, An Z, et al. Prevalence and risk factors of metabolic associated fatty liver dis-ease in Xinxiang, China[J]. Int J Environ Res Public Health, 2020, 17(6): 1818. DOI: 10.3390/ijerph17061818.

13.Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study[J]. BMC Gas-troenterol, 2021, 21(1): 212. DOI: 10.1186/s12876-021-01782-w.

14.Fan J, Liu Y, Yin S, et al. Small dense LDL cholesterol is associated with metabolic syndrome traits independently of obesity and inflammation[J]. Nutr Metab (Lond), 2019, 16: 7. DOI: 10.1186/s12986-019-0334-y.

15.Fraser A, Longnecker MP, Lawlor DA. Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004[J]. Gastroenterology, 2007, 133(6): 1814-1820. DOI: 10.1053/j.gastro.2007.08.077.

16.Speliotes EK, Massaro JM, Hoffmann U, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the framingham heart study[J]. Hepatology, 2010, 51(6): 1979-1987. DOI: 10.1002/hep.23593.

17.Simon TG, Roelstraete B, Khalili H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort[J]. Gut, 2021, 70(7): 1375-1382. DOI: 10.1136/gutjnl-2020-322786.

18.杨嘉璐，罗燕芳，单忍湖，等. 广东省东莞市30~79岁居民代谢相关脂肪性肝病患病现状[J]. 中华疾病控制杂志, 2021, 25(10): 1175-1179. [Yang JL, Luo YF, Shan RH, et al. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan city of Guangdong province[J]. Chinese Journal of Disease Control & Prevention, 2021, 25(10): 1175-1179.] DOI: 10.16462/j.cnki.zhjbkz.2021.10.011.